Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer

DISEASE CHARACTERISTICS: * Histologically confirmed diagnosis of 1 of the following: * Primary non-small cell lung cancer (NSCLC) * Any stage nonoperative NSCLC or patient refuses surgery * Any cancer with pulmonary metastatic disease (including renal cell cancer) * Stage IV disease (any T, any N, M1) * Must have 1-10 pulmonary or mediastinal masses meeting the following criteria: * At least 1 mass is appropriate for 2 sessions of core biopsy and cryotherapy with relatively easy access/low risk in nonoperative patients (or those refusing surgery) * The two dominant masses are defined as either the largest and/or those that may cause imminent morbidity from continued local progression, thereby potentially benefiting from thoracic cryotherapy alone * Optimal tumor size \> 1.0 cm * Dominant masses up to 6 cm in diameter may be considered if thorough cryotherapy coverage can be anticipated with minimal additional treatment morbidity * Measurable disease, defined as tridimensional measurements of up to 6 different pulmonary or mediastinal masses ≥ 0.5 cm by CT scan * No active pleural effusion that could be related to respiratory infection or requires further work-up * No untreated and/or unstable brain metastases PATIENT CHARACTERISTICS: * Karnofsky performance status 70-100% * Life expectancy ≥ 12 weeks * Granulocyte count ≥ 1,500/mm³ * Platelet count ≥ 50,000/mm³ * INR \< 1.5 (i.e., normal PT/PTT) * Hemoglobin ≥ 8.0 g/dL * Bilirubin ≤ 2 times upper…